Assoc. Prof. Dr. Elvina Almuradova participated as a speaker at the 11th Black Sea Oncology Days, held in Trabzon on 24–26 September 2026.

Next-Generation Cancer Treatments: ADCs and Bispecific Antibodies

Assoc. Prof. Dr. Elvina Almuradova participated as a speaker at the 11th Black Sea Oncology Days, held in Trabzon on 24–26 September 2026. In the “Future Treatments” panel on 26 September, her presentation focused on next-generation antibody–drug conjugates (ADCs) and bispecific antibodies.

These approaches reflect an important direction in oncology: developing treatments that act on specific biological targets and tailoring treatment decisions to the characteristics of each patient’s cancer.

What Are Antibody–Drug Conjugates?

Antibody–drug conjugates combine an antibody with a cancer-killing drug. The antibody recognizes a particular target on cells and helps deliver the attached drug to those cells. Some ADCs are already used in cancer treatment.

How Do Bispecific Antibodies Work?

Bispecific antibodies can bind to two different targets simultaneously. Some are designed to bring immune cells close to cancer cells, helping the immune system attack them. Their mechanism depends on the targets they recognize.

What Do These Developments Mean for Patients?

The suitability of a targeted treatment depends on the cancer’s characteristics. Biomarker testing may help identify relevant treatment targets. A targeted approach does not mean a treatment is free of side effects; benefits and risks still require careful assessment.

Dr. Almuradova’s presentation brought these next-generation antibody approaches into focus within a scientific meeting dedicated to developments in cancer treatment. Understanding how they work can also help patients ask more informed questions when discussing treatment options with their oncology team.